Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05413850 | Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection | recruiting | Phase 1 / Phase 2 | 82 | Blue Earth Therapeutics LtdINDUSTRY | 5 | May 14, 2026 | clinicaltrials |
| NCT04731844 | Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer | completed | Phase 2 | 30 | University of RochesterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04262154 |
| Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer |
| active not recruiting |
| Phase 2 |
| 28 |
| Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| May 11, 2026 |
| clinicaltrials |
| NCT03637543 | Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer | active not recruiting | Phase 2 | 29 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04986423 | ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 200 | Zenith EpigeneticsINDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT05114746 | Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan | completed | Phase 2 | 94 | Novartis PharmaceuticalsINDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05826509 | SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer(SUGAR) | active not recruiting | Phase 2 | 240 | Institut Claudius RegaudOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07025512 | 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 8, 2026 | clinicaltrials |
| NCT07384416 | QL1706 Plus Lenvatinib in Previously Treated Penile Cancer | recruiting | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07414940 | ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium(ACT-RESoLUTE) | recruiting | Phase 1 / Phase 2 | 60 | University College, LondonOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04868604 | 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)(SECuRE) | recruiting | Phase 1 / Phase 2 | 54 | Clarity Pharmaceuticals LtdINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT06212583 | High-Risk Metachronous Oligometastatic Prostate Cancer Trial(KNIGHTS) | active not recruiting | Phase 2 | 88 | University of Maryland, BaltimoreOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT07568444 | Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3) | completed | Phase 2 | 120 | University of Southern CaliforniaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07568756 | Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation | not yet recruiting | Phase 2 | 60 | University of California, IrvineOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03217747 | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 173 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05005728 | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 72 | Xencor, Inc.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT05125016 | A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 228 | Regeneron PharmaceuticalsINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT06616155 | Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07354919 | Axelopran for Advanced Cancer in Patients Receiving Opioids(AxeCan) | recruiting | Phase 2 | 34 | HealthPartners InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07568236 | A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT) | not yet recruiting | Phase 2 | 54 | Chinese University of Hong KongOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03772834 | Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer | active not recruiting | Phase 2 / Phase 3 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03067051 | Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System | recruiting | Phase 1 / Phase 2 | 66 | SpectraCure ABINDUSTRY | 4 | May 1, 2026 | clinicaltrials |
| NCT04194554 | A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer(ASCLEPIuS) | active not recruiting | Phase 1 / Phase 2 | 102 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04631744 | Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | terminated | Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06807359 | Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System | recruiting | Phase 1 / Phase 2 | 43 | SpectraCure ABINDUSTRY | 2 | May 1, 2026 | clinicaltrials |
| NCT07562438 | Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 20 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07451795 | SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC(SHARP) | recruiting | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02649855 | Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07117760 | Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 16 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05133440 | A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones | completed | Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | terminated | Phase 2 | 6 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07553988 | A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 2 | 120 | R-Pharm International, LLCINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03436654 | Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma | active not recruiting | Phase 2 | 102 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04465500 | EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer(Prostate005) | active not recruiting | Phase 2 | 60 | University of VirginiaOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05588609 | Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers | terminated | Phase 2 | 13 | Partner Therapeutics, Inc.INDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06594926 | Working Out M0 Bipolar Androgen Therapy(WOMBAT) | recruiting | Phase 2 | 69 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03522064 | Bipolar Androgen Therapy + Carboplatin in mCRPC(HiTeCH) | recruiting | Phase 2 | 30 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03682289 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 83 | Rahul AggarwalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04925648 | Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction(PICASSO) | completed | Phase 2 | 4 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04984343 | Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer(FORT) | terminated | Phase 2 | 33 | Weill Medical College of Cornell UniversityOTHER | 2 | Apr 23, 2026 | clinicaltrials |
| NCT02555189 | Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression | terminated | Phase 1 / Phase 2 | 52 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT04523207 | A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases | completed | Phase 2 | 108 | Janssen Research & Development, LLCINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04946370 | Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 52 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07407283 | A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer | recruiting | Phase 1 / Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT00951535 | A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17 | active not recruiting | Phase 2 | 251 | Cancer Trials IrelandNETWORK | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06347705 | A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer | recruiting | Phase 2 | 57 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03821792 | Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06615752 | Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients | recruiting | Phase 1 / Phase 2 | 99 | Charles Drew University of Medicine and ScienceOTHER | 1 | Apr 15, 2026 | clinicaltrials |
Data updated 24 days agoSource updated May 14, 2026source: clinicaltrials